So far this season, influenza A(H3N2) viruses have predominated, but other influenza viruses are also circulating.
Incidences of measles, mumps and pertussis have increased in the U.S. for the first time in a century (WHO, 2017). To identify the 'attitude roots' of vaccine rejection, a survey was issued online and completed by 5,323 usable participants in 24 different countries.
Changes in the 2018 adult immunization schedule from the previous year's schedule include new ACIP recommendations for the use of recombinant zoster vaccine (RZV) for adults aged 50 years or older and the use of an additional dose of measles, mumps, and rubella vaccine (MMR) in a mumps outbreak setting.
The recommended childhood and adolescent immunization schedules for 2018 have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC), the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.
Results found that among portal users, 14% (702/5,000) of portal and IVR call recipients received EHR-documented influenza vaccines.
Influenza vaccine recommendations for individuals who report an allergy to eggs.
The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.
The supplemental Biologics License Application was based on a Phase III pivotal study of the efficacy of Fluarix Quadrivalent in children 6 months through 35 months of age and on two supportive studies.
One third of HIV patients in the United States remain unvaccinated against hepatitis B.
Compared with no vaccination, the incremental cost-effectiveness ratios ranged from $20,038 to $30,084 per quality-adjusted life-year (QALY), depending on vaccination age.
The researchers found that analyses of Australian viruses generated two clusters; the vaccine virus was placed in the smaller group.
Data from both studies demonstrated the three-dose series elicits a protective immune response against diverse meningococcal group B (MenB) strains representative of prevalent strains causing invasive disease in the U.S.
The researchers report that non-covalent colocalization of two classes of complementary antigens, one to prevent the colonization of the most aggressive S. pneumoniae serotypes and another to restrict virulence transition, provides complete vaccine effectiveness.
The researchers found that at ages 2, 6, 18, and 36 months, children with at least 1 foreign-born parent were less likely to be up-to-date on recommended immunizations than children with two U.S.-born parents.
Results showed that the tablet group had a 39% reduction in clinical disease compared to placebo and a 27% reduction compared to the injectable QIV.